The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Rotigotine Mylan rotigotine Generic | Mylan S.A.S | Restless Legs Syndrome; Parkinson Disease | 🇪🇺 EU | Order → |
| Ruvise imatinib | Novartis Europharm Ltd | 🇪🇺 EU | Order → | |
| Ruxolitinib Krka ruxolitinib Generic | KRKA tovarna zdravil d.d. Novo mesto | Primary Myelofibrosis; Polycythemia Vera; Graft vs Host Disease | 🇪🇺 EU 2026-11-12 | Order → |
| Scintimun besilesomab | CIS bio international | Radionuclide Imaging | 🇪🇺 EU | Order → |
| SecreFlo | Repligen Europe Limited | 🇪🇺 EU | Order → | |
| Sepalna senaparib | Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Ovarian Epithelial | 🇪🇺 EU 2026-09-17 | Order → | |
| Sevsury surufatinib | Hutchmed Europe B.V. | Neuroendocrine Tumors | 🇪🇺 EU | Order → |
| Sildenafil FGK sildenafil | FGK Representative Service GmbH | Erectile Dysfunction | 🇪🇺 EU | Order → |
| Sinerem iron oxide | Guerbet | Magnetic Resonance Imaging | 🇪🇺 EU | Order → |
| Sitoiganap autologous glioma tumor cell lysates (inactivated);allogeneic glioma tumor cell lysates (inactivated);allogeneic glioma tumor cells (inactivated);autologous glioma tumor cells (inactivated) | Epitopoietic Research Corporation-Belgium (E.R.C.) | Glioma; Gliosarcoma | 🇪🇺 EU | Order → |
| Skojoy aflibercept Biosimilar | Amgen Technology (Ireland) UC | Wet Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Choroidal Neovascularization | 🇪🇺 EU 2025-01-30 | Order → |
| Skycovion GBP510 | SK Chemicals GmbH | 🇪🇺 EU | Order → | |
| Sliwens | Sanofi Aventis | Sleep Initiation and Maintenance Disorders | 🇪🇺 EU | Order → |
| Sohonos palovarotene Orphan | Ipsen Pharma | Myositis Ossificans | 🇪🇺 EU 2023-05-25 | Order → |
| Solithromycin Triskel EU Services solithromycin | Triskel EU Services Ltd | Tularemia; Pneumonia; Anthrax | 🇪🇺 EU | Order → |
| Solumarv insulin human Biosimilar | Marvel Lifesciences Ltd | Diabetes Mellitus | 🇪🇺 EU 2015-11-19 | Order → |
| Solumarv insulin human | Marvel Life Sciences Ltd. | 🇪🇺 EU | Order → | |
| Sondelbay teriparatide Biosimilar | Accord Healthcare S.L.U. | Osteoporosis | 🇪🇺 EU | Order → |
| Sovrima idebenone Orphan | Centocor B.V. | Friedreich Ataxia | 🇪🇺 EU 2008-11-20 | Order → |
| Spanidin gusperimus Orphan | Euro Nippon Kayaku GmbH | Wegener Granulomatosis | 🇪🇺 EU | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.